Register Login

BIOATLA, INC. (BCAB)

SymbolBCAB
NameBIOATLA, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address11085 TORREYANA ROAD, SAN DIEGO, California, 92121, United States
Telephone+1 858 558-0708
Fax—
Email—
Websitehttps://www.bioatla.com
IncorporationUNDEFINED
Incorporated On2020
Employees—
Fiscal Year12/31
Public Since—
ExchangesNASDAQ;OTC
AuditorErnst & Young LLP;
Audit StatusAUDITED
Reporting StatusU.S. Reporting: SEC Reporting
CIK0001826892
Description

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs.

Additional info from NASDAQ:
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs.

Additional info from OTC:
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The Company is currently in clinical development of several CAB drug candidates including: its two lead CAB antibody drug conjugates (“CAB ADC”), mecbotamab vedotin (BA3011), a CAB ADC targeting AXL, and ozuriftamab vedotin (BA3021), a CAB ADC targeting ROR2; evalstotug (BA3071), a CAB anti-CTLA-4 antibody; and BA3182 (CAB-EpCAM x CAB-CD3), a CAB bispecific antibody targeting EpCAM.

No news found.

Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT05808634 Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. Phase1 Advanced Adenocarcinoma Recruiting 2023-07-14 2028-09-15 ClinicalTrials.gov
NCT05271604 A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic S… Phase2 Head and Neck Cancer Completed 2022-12-13 2025-09-22 ClinicalTrials.gov
NCT05180799 A Phase 1/2 Study of BA3071 in Patients With Solid Tumors Phase1 NSCLC Active_Not_Recruiting 2022-08-03 2026-06-30 ClinicalTrials.gov
NCT04681131 CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC Phase2 Non-Small-Cell Lung Cancer Completed 2021-03-17 2025-07-09 ClinicalTrials.gov
NCT03853343 Seaweed Extract Supplementation and Metabolic Biomarkers Na Metabolic Syndrome Completed 2018-06-28 2022-01-30 ClinicalTrials.gov
NCT03504488 CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Can… Phase1 Non Small Cell Lung Cancer Completed 2018-06-27 2024-12-30 ClinicalTrials.gov
NCT03425279 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sar… Phase1 Undifferentiated Pleomorphic Sarcoma Completed 2018-02-15 2025-01-08 ClinicalTrials.gov
Total clinical trials: 7
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Toripalimab Other Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
ENB003 Other Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
BA3021 Other Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
BA3011 Other Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
Durvalumab Other Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
Placebo Other Approved Metabolic Syndrome COMPLETED NCT03853343
Seaweed extract Other Approved Metabolic Syndrome COMPLETED NCT03853343
Placebo Other Approved Metabolic Syndrome COMPLETED NCT03853343
Seaweed extract Other Approved Metabolic Syndrome COMPLETED NCT03853343
PD-1 inhibitor Other Phase PHASE1 Non Small Cell Lung Cancer COMPLETED NCT03504488
CAB-ROR2-ADC Other Phase PHASE1 Non Small Cell Lung Cancer COMPLETED NCT03504488
Pemetrexed (Alimta) Other Phase PHASE1 NSCLC ACTIVE_NOT_RECRUITING NCT05180799
Pembrolizumab Other Phase PHASE1 NSCLC ACTIVE_NOT_RECRUITING NCT05180799
Nivolumab Other Phase PHASE1 NSCLC ACTIVE_NOT_RECRUITING NCT05180799
BA3071 Other Phase PHASE1 NSCLC ACTIVE_NOT_RECRUITING NCT05180799
PD-1 inhibitor Other Phase PHASE1 Undifferentiated Pleomorphic Sarcoma COMPLETED NCT03425279
CAB-AXL-ADC Other Phase PHASE1 Undifferentiated Pleomorphic Sarcoma COMPLETED NCT03425279
BA3182 Other Phase PHASE1 Advanced Adenocarcinoma RECRUITING NCT05808634
PD-1 inhibitor Other Phase PHASE2 Non-Small-Cell Lung Cancer COMPLETED NCT04681131
CAB-AXL-ADC Other Phase PHASE2 Non-Small-Cell Lung Cancer COMPLETED NCT04681131
Cetuximab Other Phase PHASE2 Head and Neck Cancer COMPLETED NCT05271604
Evalstotug (BA3071) Other Phase PHASE2 Head and Neck Cancer COMPLETED NCT05271604
Pembrolizumab Other Phase PHASE2 Head and Neck Cancer COMPLETED NCT05271604
Ozuriftamab Vedotin Other Phase PHASE2 Head and Neck Cancer COMPLETED NCT05271604
Toripalimab Other Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
ENB003 Other Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
BA3021 Other Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
BA3011 Other Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
Durvalumab Other Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
BA3182 DRUG Phase PHASE1 Advanced Adenocarcinoma RECRUITING NCT05808634
Cetuximab BIOLOGICAL Phase PHASE2 Head and Neck Cancer COMPLETED NCT05271604
Evalstotug (BA3071) BIOLOGICAL Phase PHASE2 Head and Neck Cancer COMPLETED NCT05271604
Ozuriftamab Vedotin BIOLOGICAL Phase PHASE2 Head and Neck Cancer COMPLETED NCT05271604
Pemetrexed (Alimta) DRUG Phase PHASE1 NSCLC ACTIVE_NOT_RECRUITING NCT05180799
Pembrolizumab BIOLOGICAL Phase PHASE2 Head and Neck Cancer COMPLETED NCT05271604
Nivolumab BIOLOGICAL Phase PHASE1 NSCLC ACTIVE_NOT_RECRUITING NCT05180799
BA3071 BIOLOGICAL Phase PHASE1 NSCLC ACTIVE_NOT_RECRUITING NCT05180799
Toripalimab DRUG Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
ENB003 DRUG Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
BA3021 DRUG Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
BA3011 DRUG Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
Durvalumab DRUG Phase PHASE2 Ovarian Cancer RECRUITING NCT04918186
CAB-ROR2-ADC BIOLOGICAL Phase PHASE1 Non Small Cell Lung Cancer COMPLETED NCT03504488
PD-1 inhibitor BIOLOGICAL Phase PHASE2 Non-Small-Cell Lung Cancer COMPLETED NCT04681131
CAB-AXL-ADC BIOLOGICAL Phase PHASE2 Non-Small-Cell Lung Cancer COMPLETED NCT04681131
Total products: 45